Lorenza Chiara Zingale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lorenza Chiara Zingale has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Marco Cicardi
University of Milan
27 shared publications Andrea Zanichelli
Department of Clinical Sciences, Luigi Sacco Hospital
9 shared publicationsEmanuela Pappalardo
Department of Medical Sciences, University of Milan, Ospedale L. Sacco, Via G.B. Grassi 74, Milan, Italy
7 shared publicationsAngelo Agostoni
University of Milan, Italy
6 shared publicationsChristoph Bucher
4 shared publicationsDaniela Lambertenghi Deliliers
4 shared publications
Latest Publications
- Open Access
- 1 February 2019
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 15, 19-25
Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA)
Purpose: Numerous studies on thromboembolic prevention for non-valvular atrial fibrillation (NVAF) have shown either equal or better efficacy and safety of non-vitamin K oral anticoagulants (NOACs) compared to warfarin, even for patients aged ≥75 years. Data on elderly patients, in particular, octogenarians, are lacking. Paradoxically, this population is the one with the highest risk of bleeding and stroke with a worse prognosis. This study aims to describe safety and effectiveness of NOACs in an elderly comorbid population. Patients and methods: REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA) is a prospective observational study enrolling consecutive NVAF patients started on NOACs and followed up to 1 year (at 1, 6, 12 months). The primary endpoint was the incidence rate of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB). The secondary endpoints were the incidence of 1) stroke or systemic embolism, 2) hospitalization, 3) death, and 4) drug-related adverse events. Results: We enrolled 227 patients aged 81.6±6.1 years (range 67–95 years; ≥80 years in 59.4%). The median CHA2DS2-VASc was 5 (IQR 4–5) and HAS-BLED was 4 (IQR 3–5). The estimated glomerular filtration rate was 59.27±24.12 mL/min. During follow-up, only 10 MB and 23 CRNMB occurred, with a total incidence of 4.4% (95% CI: 1.7%–7.17%) and 5.7% (95% CI: 2.68%–8.72%), respectively. There were 2 cerebral ischemic events, with a total incidence of 0.88% (95% CI: 0.84%–0.92%), 23 NOAC-related hospitalizations, no NOAC-related deaths, and 4 minor drug-related adverse effects. Conclusion: In a population of aged and clinically complex patients, mainly octogenarians, NOACs were safe and effective.
- 1 February 2019
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 15, 19-25
Open AccessNon-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA)
Purpose: Numerous studies on thromboembolic prevention for non-valvular atrial fibrillation (NVAF) have shown either equal or better efficacy and safety of non-vitamin K oral anticoagulants (NOACs) compared to warfarin, even for patients aged ≥75 years. Data on elderly patients, in particular, octogenarians, are lacking. Paradoxically, this population is the one with the highest risk of bleeding and stroke with a worse prognosis. This study aims to describe safety and effectiveness of NOACs in an elderly comorbid population. Patients and methods: REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA) is a prospective observational study enrolling consecutive NVAF patients started on NOACs and followed up to 1 year (at 1, 6, 12 months). The primary endpoint was the incidence rate of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB). The secondary endpoints were the incidence of 1) stroke or systemic embolism, 2) hospitalization, 3) death, and 4) drug-related adverse events. Results: We enrolled 227 patients aged 81.6±6.1 years (range 67–95 years; ≥80 years in 59.4%). The median CHA2DS2-VASc was 5 (IQR 4–5) and HAS-BLED was 4 (IQR 3–5). The estimated glomerular filtration rate was 59.27±24.12 mL/min. During follow-up, only 10 MB and 23 CRNMB occurred, with a total incidence of 4.4% (95% CI: 1.7%–7.17%) and 5.7% (95% CI: 2.68%–8.72%), respectively. There were 2 cerebral ischemic events, with a total incidence of 0.88% (95% CI: 0.84%–0.92%), 23 NOAC-related hospitalizations, no NOAC-related deaths, and 4 minor drug-related adverse effects. Conclusion: In a population of aged and clinically complex patients, mainly octogenarians, NOACs were safe and effective.
- 1 November 2011
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 29 (11) , 2273-2277
Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema
Objective To investigate, for the first time, the frequency of recurrences of angiotensin-converting enzyme inhibitor (ACE-I)-related angioedema after the discontinuation of ACE-I. Methods This retrospective study was conducted in an outpatient tertiary-level centre for a total period of 173 months (about 14 years). Consecutive patients with recurrent angioedema symptoms, initiated during treatment with an ACE-I, who had been followed for at least 12 months after discontinuation of the drug were eligible. The primary study variable was the incidence of recurrences of angioedema after ACE-I discontinuation. Angioedema location, type of ACE-I and indication for this treatment and the drugs prescribed after the discontinuation of ACE-I were also evaluated. Results In total, 111 patients were followed; 54 of them (49%) were on enalapril. After discontinuation from ACE-I, 51 patients (46%) had further recurrences of angioedema; in 18 relapsers (16% of the total), the frequency of angioedema recurrences remained unchanged when compared with that reported during ACE-I treatment. The large majority of relapsers (88%) had the first recurrence of angioedema within the first month since ACE-I discontinuation. The switch to a different antihypertensive therapy did not seem associated with a reduction in the frequency of angioedema attacks. Conclusion Even with all the limitations on any observational analysis, this long-term study suggests for the first time that patients with angioedema started while on ACE-I treatment seem to have a condition predisposing to angioedema that is elicited by the treatment with these drugs. Further studies in this field appear advocated due to the potential severity of angioedema attacks.
- 1 November 2011
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 29 (11) , 2273-2277
Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema
Objective To investigate, for the first time, the frequency of recurrences of angiotensin-converting enzyme inhibitor (ACE-I)-related angioedema after the discontinuation of ACE-I. Methods This retrospective study was conducted in an outpatient tertiary-level centre for a total period of 173 months (about 14 years). Consecutive patients with recurrent angioedema symptoms, initiated during treatment with an ACE-I, who had been followed for at least 12 months after discontinuation of the drug were eligible. The primary study variable was the incidence of recurrences of angioedema after ACE-I discontinuation. Angioedema location, type of ACE-I and indication for this treatment and the drugs prescribed after the discontinuation of ACE-I were also evaluated. Results In total, 111 patients were followed; 54 of them (49%) were on enalapril. After discontinuation from ACE-I, 51 patients (46%) had further recurrences of angioedema; in 18 relapsers (16% of the total), the frequency of angioedema recurrences remained unchanged when compared with that reported during ACE-I treatment. The large majority of relapsers (88%) had the first recurrence of angioedema within the first month since ACE-I discontinuation. The switch to a different antihypertensive therapy did not seem associated with a reduction in the frequency of angioedema attacks. Conclusion Even with all the limitations on any observational analysis, this long-term study suggests for the first time that patients with angioedema started while on ACE-I treatment seem to have a condition predisposing to angioedema that is elicited by the treatment with these drugs. Further studies in this field appear advocated due to the potential severity of angioedema attacks.
- 1 September 2008
- Published by Elsevier in Journal of Immunological Methods
- Vol. 338 (1-2) , 14-20
Functional C1-Inhibitor diagnostics in hereditary angioedema: Assay evaluation and recommendations
- 1 September 2008
- Published by Elsevier in Journal of Immunological Methods
- Vol. 338 (1-2) , 14-20
Functional C1-Inhibitor diagnostics in hereditary angioedema: Assay evaluation and recommendations
- 1 August 2008
- Published by Elsevier in Molecular Immunology
- Vol. 45 (13) , 3536-3544
Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: Functional and structural correlates
- 1 August 2008
- Published by Elsevier in Molecular Immunology
- Vol. 45 (13) , 3536-3544
Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: Functional and structural correlates
- 1 June 2008
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 20 (6) , 583-587
Successful resolution of bowel obstruction in a patient with hereditary angioedema
Hereditary angioedema (HAE), a rare genetic disorder caused by a deficiency of the C1 esterase inhibitor, leads to an episodic, self-limiting increase in vascular permeability. Related symptoms commonly include recurrent, intractable abdominal pain, vomiting, and/or diarrhea. DX-88 (ecallantide), a 60-amino acid recombinant protein discovered through phage display technology, is a highly specific, potent inhibitor of human plasma kallikrein that has been used successfully in the treatment of patients experiencing acute HAE attacks. This case study involves a 65-year-old woman who presented with severe abdominal pain, cramping, and nausea. The study describes the use of a video obtained by capsule endoscopy for the direct imaging of bowel occlusion in a patient with HAE that resolved upon treatment with DX-88. After administration of DX-88, 80 mg intravenously, abdominal pain and nausea resolved within 30 min. Capsule endoscopy demonstrated a coincident resolution of the bowel wall edema, with a return to normal within approximately 1.5 h of DX-88 administration. This case study demonstrates that DX-88 can produce dramatic clinical benefits in a patient with an acute abdominal HAE attack, resolving both symptoms and pathologic signs. Furthermore, it illustrates the usefulness of videos obtained from capsule endoscopy in identifying the presence of bowel occlusion and demonstrating its subsequent rapid resolution upon administration of DX-88.
- 1 June 2008
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 20 (6) , 583-587
Successful resolution of bowel obstruction in a patient with hereditary angioedema
Hereditary angioedema (HAE), a rare genetic disorder caused by a deficiency of the C1 esterase inhibitor, leads to an episodic, self-limiting increase in vascular permeability. Related symptoms commonly include recurrent, intractable abdominal pain, vomiting, and/or diarrhea. DX-88 (ecallantide), a 60-amino acid recombinant protein discovered through phage display technology, is a highly specific, potent inhibitor of human plasma kallikrein that has been used successfully in the treatment of patients experiencing acute HAE attacks. This case study involves a 65-year-old woman who presented with severe abdominal pain, cramping, and nausea. The study describes the use of a video obtained by capsule endoscopy for the direct imaging of bowel occlusion in a patient with HAE that resolved upon treatment with DX-88. After administration of DX-88, 80 mg intravenously, abdominal pain and nausea resolved within 30 min. Capsule endoscopy demonstrated a coincident resolution of the bowel wall edema, with a return to normal within approximately 1.5 h of DX-88 administration. This case study demonstrates that DX-88 can produce dramatic clinical benefits in a patient with an acute abdominal HAE attack, resolving both symptoms and pathologic signs. Furthermore, it illustrates the usefulness of videos obtained from capsule endoscopy in identifying the presence of bowel occlusion and demonstrating its subsequent rapid resolution upon administration of DX-88.
- 26 November 2007
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 8 (18) , 3173-3181
The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema
(2007). The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opinion on Pharmacotherapy: Vol. 8, No. 18, pp. 3173-3181.
- 26 November 2007
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 8 (18) , 3173-3181
The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema
(2007). The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opinion on Pharmacotherapy: Vol. 8, No. 18, pp. 3173-3181.
- 2 September 2007
- Published by Elsevier
- p. 695-701
C1 INHIBITOR AUTOANTIBODIES
- 1 September 2007
- Published by Elsevier in Molecular Immunology
- Vol. 44 (16) , 3858-3861
Established and new treatments for hereditary angioedema: An update
- 1 September 2007
- Published by Elsevier in Molecular Immunology
- Vol. 44 (16) , 3858-3861
Established and new treatments for hereditary angioedema: An update
- Open Access
- 1 June 2007
- Published by Elsevier in Immunobiology
- Vol. 212 (4-5) , 325-331
The deficiency of C1 inhibitor and its treatment
- 1 June 2007
- Published by Elsevier in Immunobiology
- Vol. 212 (4-5) , 325-331
Open AccessThe deficiency of C1 inhibitor and its treatment